Canaccord Genuity expands Equity Research group with addition to its healthcare practice

NEW YORK, June 5, 2014 /CNW/ - Canaccord Genuity is pleased to announce the expansion of its Healthcare Equity Research team with the hiring of Corey Davis, Ph.D., as a Managing Director covering Specialty Pharmaceuticals, with a focus in certain therapeutics areas within the biotech sector.

"We are pleased to welcome Corey Davis to the Canaccord Genuity Healthcare team," commented Stephen Buell, Global Head of Equity Research at Canaccord Genuity Inc. "Corey's versatile experience enhances Canaccord Genuity's ability to continue to provide clients with high-quality, independent, global equity research coverage within the dynamic and opportunity-rich healthcare sector."

Mr. Davis brings over 16 years of sell-side experience covering Specialty Pharmaceuticals companies, most of those years at JP Morgan and at Jefferies.  He is widely recognized for his expertise on a broad range of key issues within the industry, including IP law, CNS-related disorders, clinical trial design, financial modelling, and has deep relationships with thought leaders in the industry. Mr. Davis earned a BA in Biology from Middlebury College in 1991 and a Ph.D. in Molecular Biology at Princeton University in 1997.

At Canaccord Genuity, Corey will establish strong coverage of key Specialty Pharmaceuticals names, as well as a series of later-stage biopharmaceutical companies that offer investors a broad range of investment opportunities in drug development.

Canaccord Genuity's global coverage of the Healthcare sector now includes eight analysts across three continents, covering Biotechnology, Specialty Pharmaceuticals, Medical Devices, Medical Diagnostics, Life Sciences Tools and Healthcare Services. At present, Canaccord Genuity has nearly 150 equity research professionals globally and more than 950 companies under coverage.

ABOUT CANACCORD GENUITY:

Canaccord Genuity is the global capital markets division of Canaccord Genuity Group Inc. (TSX: CF, LSE: CF.), offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from offices in 11 countries worldwide. Our team of nearly 1,000 capital markets and advisory professionals has industry and transactional expertise in 18 key sectors of the global economy. We are committed to providing valued services to our clients throughout the entire lifecycle of their business and operating as a gold standard independent investment bank - expansive in resources and reach, but targeted in industry expertise, market focus and individual client attention.

More information is available at www.canaccordgenuity.com.

ABOUT CANACCORD GENUITY GROUP INC.:

Through its principal subsidiaries, Canaccord Genuity Group Inc. (the "Company") is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services. The Company has offices in 11 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK and Europe. Canaccord Genuity, the international capital markets division, operates in Canada, the U.S., the U.K., France, Germany, Ireland, Hong Kong, mainland China, Singapore, Australia and Barbados. To us there are no foreign markets.™

Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.

SOURCE: Canaccord Financial Inc.

Nadine Miller
Canaccord Genuity
617.371.3842
[email protected]